Zymeworks sued for failing to pay contingent value rights (CVRs)
Zymeworks Inc. is being sued by acquisition target Theravance Biopharma after failing to pay out agreed-upon contingent value rights to shareholders following a 2026 merger. The filing confirms a breach of contract claims regarding the Merger Agreement and subsequent CVR obligations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed